Is Curaleaf Holdings (TSX:CURA) Now At An Attractive Price After Recent Share Pullback?

Simply Wall St

Tue, February 17, 2026 at 1:35 PM GMT+9 4 min read

In this article:

CURLF

+1.68%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

If you are wondering whether Curaleaf Holdings at around US$3.31 is starting to look like value or still carries a premium, you are not alone.

The stock has seen a 1.2% decline over the last 7 days and is down 10.3% over the past month, yet it still sits on a 59.9% return over the last year after deeper 3 year and 5 year losses of 36.3% and 84.2% respectively.

Recent attention on Curaleaf has centered on ongoing developments in the cannabis sector and regulatory progress in key markets, which often influences sentiment toward larger multi state operators. Investors are watching how these headlines line up with the share price pulling back in the short term while remaining higher than a year ago.

On our framework, Curaleaf currently holds a valuation score of 5 out of 6, which we will unpack using several standard valuation approaches before considering a broader way to think about what that score really means for you.

Curaleaf Holdings delivered 59.9% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Curaleaf Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth by projecting its future cash flows and then discounting those back to today using a required rate of return.

For Curaleaf Holdings, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is $65.45 million, and analysts have supplied explicit forecasts out to 2027, with Simply Wall St extrapolating further annual cash flows out to 2035. Within that set of projections, free cash flow is estimated to reach $436.70 million in 2035 based on the provided estimates and extrapolations.

When all these future cash flows are discounted back to today, the model arrives at an estimated intrinsic value of $15.50 per share. Against a recent share price around CA$3.31, this suggests the stock is 78.6% undervalued according to this DCF analysis.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Curaleaf Holdings is undervalued by 78.6%. Track this in your watchlist or portfolio, or discover 5 more high quality undervalued stocks.

CURA Discounted Cash Flow as at Feb 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Curaleaf Holdings.

Approach 2: Curaleaf Holdings Price vs Sales

For companies that are not consistently profitable, price based on revenue can often be more useful than earnings-based metrics, which is why P/S is the preferred lens for Curaleaf Holdings.

Story Continues  

In simple terms, higher growth expectations and lower perceived risk usually justify a higher multiple, while slower expected growth and higher risk tend to align with a lower or even discounted multiple. That same logic applies when you look at revenue-based ratios like P/S.

Curaleaf currently trades on a P/S of 1.48x. That sits above the Pharmaceuticals industry average of 0.87x, but below a peer group average of 2.59x. To go a step further, Simply Wall St calculates a proprietary Fair Ratio of 1.75x for Curaleaf, which reflects factors such as its earnings profile, industry, profit margin, market cap and risk characteristics.

The Fair Ratio is more tailored than a simple peer or industry comparison, because it adjusts for company-specific traits rather than assuming all firms in the same sector deserve similar multiples.

Comparing Curaleaf’s current 1.48x P/S to the Fair Ratio of 1.75x indicates that, on this metric, the shares appear to be trading below that fair-value estimate.

Result: UNDERVALUED

TSX:CURA P/S Ratio as at Feb 2026

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 3 top founder-led companies.

Upgrade Your Decision Making: Choose your Curaleaf Holdings Narrative

Earlier we mentioned that there is an even better way to think about valuation, and on Simply Wall St that means using Narratives. In this approach you set out your story for Curaleaf Holdings, link it to specific expectations for future revenue, earnings and margins, and the platform converts that story into a financial forecast and a fair value. You can then easily compare this with the current share price to help decide whether you see Curaleaf as closer to a CA$2.65 outcome or a CA$4.51 outcome. All of this is hosted on the Community page and is automatically refreshed as new news or earnings come in so your view and fair value stay aligned with the latest information.

Do you think there’s more to the story for Curaleaf Holdings? Head over to our Community to see what others are saying!

TSX:CURA 1-Year Stock Price Chart

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include CURA.TO.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info